

NUROSENE COMMENCES TRADING ON THE FRANKFURT STOCK EXCHANGE

TORONTO, ON, JULY 2, 2021 – Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV), a health-tech company focused on mental wellness, is pleased to announce that its common shares have commenced trading on the Frankfurt Stock Exchange under the ticker symbol “8TV”.

The Company commenced trading on July 1st, 2021 and has been assigned an International Securities Identification Number (ISIN: CA64132U1003) and a German Securities Identification Number (WKN: A3CRX6). The Company’s common shares continue to be listed on the Canadian Securities Exchange (“CSE”) under the symbol “MEND”.

Nurosene CEO, Ranj Bath said: “Nurosene has enjoyed tremendous investor support since our debut on the CSE. We are excited to share our story with international investors who want to participate in the growth of our Company. This is only the first step on our mission to address mental wellness, not only in Canada, but on a global scale.”

The Frankfurt Stock Exchange (FWB) is one of the world's largest international trading centers for securities. Operated by the Deutsche Boerse AG, FWB, is the largest of Germany’s seven stock exchanges, and is responsible for approximately 90 percent of all securities traded in Germany. The FWB facilitates advanced electronic trading, settlement and information systems and enables cross-border trading for international investors.

About Nurosene

Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Its mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI and machine learning. With its team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments. The company is based in Toronto, Ontario.

For more information, visit www.nurosene.com | shop.nurosene.com

KCSA Strategic Communications | Valter Pinto, Managing Director | Valter@KCSA.com | (212) 896-1254

Blake Sing, Chief Financial Officer | investors@nurosene.com | (416) 859-8838

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect," "likely," "may," "will," "should," "intend," "anticipate," "potential," "proposed", "estimate," and

other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may," "would," or "will," happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, activities of the Company's listing on the Frankfurt Stock Exchange and international strategy.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.